Research progress on the application of glucocorticoids in bronchopul-monary dysplasia in neonates
Bronchopulmonary dysplasia(BPD)is common chronic lung disease in neonates,especially in premature infants,which has a significant impact on the survival and long-term quality of life of children.Glucocorticoids are the key drugs for the prevention and treatment of neonatal BPD,but there is no clear and unified standard administration regimen,and the efficacy and possible risks of each regimen need to be weighed.In this paper,the selection of glucocorticoid drug varieties,the timing of administration,the influence of different administration routes and dose selection on clinical efficacy and safety are reviewed,and the best treatment plan of glucocorticoid for BPD is summarized from the existing evidence-based medical evidence.Current evidence shows that intravenous Dexamethasone(＜4 mg/kg)used in late postnatal period for 7-10 days is effective and safe for the prevention and treatment of BPD.To reduce the risk of adverse neurodevelopmental outcomes,local administration regiments(inhaled Budesonide,400 to 1 000 μg/d,duration ≥ 14 days)have been emerging in recent years and may be associated with reduced BPD morbidity and mortality,but their efficacy and safety need to be further validated in larger randomized clinical trials.
万方数据
维普
